Lomefloxacin

Lomefloxacin

SCHEMBL34609

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

gyrAgyrB

The experimentally established mechanism targets of Lomefloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 1.00
HSD17B10 Q99714 5/20 1.00
ALDH1A1 P00352 5/20 1.00
HPGD P15428 5/20 1.00
PMP22 Q01453 1/20 0.98
KCNH2 Q12809 4/20 0.62
POLB P06746 1/20 0.62
PRKD3 O94806 1/20 0.62
ALOX15 P16050 1/20 0.62
OPRM1 P35372 1/20 0.62
CLK2 P49760 1/20 0.62
CLK4 Q9HAZ1 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
LMNA P02545 3/20 0.54
BRD4 O60885 1/20 0.54
TSHR P16473 1/20 0.54
HTT P42858 1/20 0.54
CYP2J2 P51589 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
CYP2C9 P11712 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lomefloxacin SCHEMBL34610 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL29895425 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL9226104 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL29388501 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL133835 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL8912235 0.99 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL30034879 0.99 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL42051 0.99 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL42052 0.99 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22
Lomefloxacin SCHEMBL2636428 0.99 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 24067 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624057-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2026-05-12 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
EP-4434588-B1 AEROSOL DELIVERY DEVICE PARI PHARMA GMBH (DE) 2026-04-08 EP claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4694929-A1 METHODS FOR TREATING CORNEAL INJURIES Lin, Sung-Jan (TW) 2026-02-18 EP claimed
US-20260027140-A1 COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA ATOPIC MEDICAL INC (US) 2026-01-29 US claimed
EP-4659014-A1 EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING President And Fellows Of Harvard College (US) 2025-12-10 EP claimed
US-12465623-B2 Use of parasites and extracellular vesicles obtained from parasites in cancer treatment YEDITEPE UNIVERSITESI (TR) 2025-11-11 US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-0322892-B1 FREEZE-DRIED PHARMACEUTICAL PREPARATIONS FOR PARENTERAL USE KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1992-03-25 EP claimed
EP-0470252-A1 ANTI-HIV DRUG DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1992-02-12 EP claimed
EP-0443381-A1 Effervescent composition, its production and use Takeda Chemical Industries, Ltd. (JP) 1991-08-28 EP claimed
WO-1991009616-A1 QUINOLONE ANTIBIOTICS ENCAPSULATED IN LIPID VESICLES YALE UNIVERSITY (US) 1991-07-11 WO claimed
EP-0394553-A2 Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1990-10-31 EP claimed
EP-0322892-A1 Freeze-dried pharmaceutical preparations for parenteral use KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1989-07-05 EP claimed
US-4780465-A ISOTONIZED WITH POLYALCOHOL OR BORIC ACID; MICROBIOCIDE HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1988-10-25 US claimed
EP-0140116-B1 A 6-FLUORO-1,4-DIHYDRO-4-OXO-7-SUBSTITUTED PIPERAZINYL-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE AND THE METHOD FOR PREPARING THE SAME Hokuriku Pharmaceutical Co.,Ltd (JP) 1988-05-25 EP claimed
US-4528287-A 6-Fluoro-1, 4-dihydro-4-oxo-7-substituted piperazinylquinoline-3-carboxylic acids and the method for preparing the same HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1985-07-09 US claimed
EP-0140116-A1 A 6-fluoro-1,4-dihydro-4-oxo-7-substituted piperazinyl-quinoline-3-carboxylic acid derivative and the method for preparing the same Hokuriku Pharmaceutical Co.,Ltd (JP) 1985-05-08 EP claimed